Category Archives: PRESS RELEASES

Komet Announces Closing of Previously Announced Transaction Regarding the Sale of the Dabia Sud Property in Mali

MONTREAL, July 03, 2020 (GLOBE NEWSWIRE) — Further to its news release dated May 15, 2020 announcing the entering into of a binding letter of intent, Komet Resources Inc. (“Komet” or the “Company”; TSX-V: KMT) is pleased to announce that it has closed, on July 2, 2020 (the “Closing Date”) its previously announced transaction relating to the sale of all of the issued and outstanding shares of its wholly owned subsidiary Komet Mali SARL (“Komet Mali”), which owns the Dabia Sud project, to RosCan Gold Corporation (“RosCan“; TSX-V: ROS).

The disposition price was CAD $ 3.2 million. Komet received on Closing Date CAD $1.6 million in cash and an aggregate of 4,060,336 common shares of RosCan, each such common share having a deemed issuance value of CAD $0.394, representing the 5-day volume weighted average price of RosCan’s common shares as of the trading day prior to the Closing Date.

RosCan shares issued in the transaction are subject to a voluntary hold period for 6 months after the Closing Date. Komet has entered into a voting trust agreement with RosCan pursuant to which it has agreed to vote the issued RosCan shares in favour of management’s recommendations for a period of 12 months.

Investor Relations/information :

Mr. Robert Wares, Chairman and interim President:  514-951-4235 / r.wares@kometgold.com

More information about the Corporation is available at: http://kometgold.com.

Forward-looking Statements

This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavourable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Komet Announces Closing of Previously Announced Transaction Regarding the Sale of the Dabia Sud Property in Mali

MONTREAL, July 03, 2020 (GLOBE NEWSWIRE) — Further to its news release dated May 15, 2020 announcing the entering into of a binding letter of intent, Komet Resources Inc. (“Komet” or the “Company”; TSX-V: KMT) is pleased to announce that it has closed, on July 2, 2020 (the “Closing Date”) its previously announced transaction relating to the sale of all of the issued and outstanding shares of its wholly owned subsidiary Komet Mali SARL (“Komet Mali”), which owns the Dabia Sud project, to RosCan Gold Corporation (“RosCan“; TSX-V: ROS).

The disposition price was CAD $ 3.2 million. Komet received on Closing Date CAD $1.6 million in cash and an aggregate of 4,060,336 common shares of RosCan, each such common share having a deemed issuance value of CAD $0.394, representing the 5-day volume weighted average price of RosCan’s common shares as of the trading day prior to the Closing Date.

RosCan shares issued in the transaction are subject to a voluntary hold period for 6 months after the Closing Date. Komet has entered into a voting trust agreement with RosCan pursuant to which it has agreed to vote the issued RosCan shares in favour of management’s recommendations for a period of 12 months.

Investor Relations/information :

Mr. Robert Wares, Chairman and interim President:  514-951-4235 / r.wares@kometgold.com

More information about the Corporation is available at: http://kometgold.com.

Forward-looking Statements

This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavourable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Novavax Announces Updates to Leadership Team

Frank Czworka appointed SVP, Global Sales

Brian Webb promoted to SVP, Manufacturing

GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates.

“Frank’s extensive commercial and sales expertise will be invaluable to Novavax’ transformation into a commercial stage organization,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Brian has been instrumental in the recent expansion and alignment of our manufacturing capabilities and supply partnerships. I am confident that the company will benefit greatly from their mutual expertise as we advance our efforts to bring NVX‑CoV2373 and NanoFlu to market.”

Mr. Czworka brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as Vice President, Global Customer Engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the University of Central Florida.

“This is an exciting time to join Novavax, with much to be accomplished as we advance our COVID-19 candidate and prepare the regulatory submission for NanoFlu,” said Mr. Czworka. “I’m excited to contribute to the team so that we can positively impact the lives of patients and reduce the global burden of these infectious diseases.”

Mr. Webb joined Novavax in May 2014 with responsibility for internal and external manufacturing. Prior to joining Novavax, Mr. Webb held numerous operational leadership roles at GlaxoSmithKline and Human Genome Sciences where he had the opportunity to take multiple products from early clinical stage through licensure and launch. He received a bachelor of science degree in biology from Salisbury University and a master of science degree in biotechnology from Johns Hopkins University.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

Novavax Announces Updates to Leadership Team

Frank Czworka appointed SVP, Global Sales

Brian Webb promoted to SVP, Manufacturing

GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates.

“Frank’s extensive commercial and sales expertise will be invaluable to Novavax’ transformation into a commercial stage organization,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Brian has been instrumental in the recent expansion and alignment of our manufacturing capabilities and supply partnerships. I am confident that the company will benefit greatly from their mutual expertise as we advance our efforts to bring NVX‑CoV2373 and NanoFlu to market.”

Mr. Czworka brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as Vice President, Global Customer Engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the University of Central Florida.

“This is an exciting time to join Novavax, with much to be accomplished as we advance our COVID-19 candidate and prepare the regulatory submission for NanoFlu,” said Mr. Czworka. “I’m excited to contribute to the team so that we can positively impact the lives of patients and reduce the global burden of these infectious diseases.”

Mr. Webb joined Novavax in May 2014 with responsibility for internal and external manufacturing. Prior to joining Novavax, Mr. Webb held numerous operational leadership roles at GlaxoSmithKline and Human Genome Sciences where he had the opportunity to take multiple products from early clinical stage through licensure and launch. He received a bachelor of science degree in biology from Salisbury University and a master of science degree in biotechnology from Johns Hopkins University.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

Imperial Capital Hires Distressed Debt Trading Veteran, Simon Mullaly, to Head New European Private Credit Group

LOS ANGELES, July 02, 2020 (GLOBE NEWSWIRE) — Imperial Capital Group, LLC (“Imperial Capital”), announced today that Simon Mullaly has returned to the markets to launch a European Private Credit Group in which he will serve as Head Trader.  The European Private Credit Group will source private European credit investment opportunities for Imperial Capital’s institutional investors in both Europe and the US.

“We believe that Simon is rejoining the market at the opportune time when there is an increasing appetite for special situations trading in both Europe and the US,” said Tim Sullivan, President of Imperial Capital, LLC. “The addition of Simon to head a dedicated European Private Credit effort affirms the Company’s vision to expand our existing credit sales & trading franchise into non-cusip trading solutions for our clients.”

Simon Mullaly joins Imperial Capital as a Managing Director and Head of the European Private Credit Trading Group.  He will be based in Stamford, CT.  Previously, Mr. Mullaly was the founder and CEO of Yorvik Partners, a European based credit brokerage firm that specialized in distressed debt before being acquired by Sterne Agee in late 2013.  Prior to founding Yorvik, Mr. Mullaly managed trading desks for Deutsche Bank, AG and Lehman Brothers in London.  Mr. Mullaly earned an MBA from The Wharton School at the University of Pennsylvania and a BSc at Nottingham Trent University.

“I am excited to join Imperial Capital’s well-established fixed income platform that includes bespoke research,” said Simon Mullaly.  “I believe that we can leverage Imperial Capital’s platform to grow a Private European Credit group that complements the growth of private debt in Europe as a credible asset class that is systemically changing and here to stay.”

About Imperial Capital, LLC

Imperial Capital, LLC is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer’s capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital, LLC has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital, LLC can be found at www.imperialcapital.com.

For more information regarding Imperial Capital, please contact:
Mark Martis
+1 310 246 3674
mmartis@imperialcapital.com

About Imperial Capital (International), LLP

Imperial Capital International, founded in 2011, is an affiliate of Imperial Capital, LLC with an office in central London.  Complementing Imperial Capital’s existing corporate credit sales and trading franchise, Imperial Capital International expanded the Imperial Capital franchise into the EEA.  The company focuses on the entire credit spectrum and takes a full capital structure research approach to supplement sales and trading services to its European institutional clients.

For more information regarding Imperial Capital (International), LLP, please contact:
Emma McClintock
+ 44 (0) 207 650 5429
emcclintock@imperialcapital.com